Wikipedia

Transfection

Transfectionis the process of deliberately introducing naked or purifiednucleic acidsintoeukaryoticcells.[1][2]It may also refer to other methods and cell types, although other terms are often preferred: "transformation"is typically used to describe non-viralDNAtransfer inbacteriaand non-animaleukaryoticcells, including plant cells. In animal cells, transfection is the preferred term, as the term "transformation" is also used to refer to a cell's progression to a cancerous state (carcinogenesis).Transductionis often used to describe virus-mediated gene transfer into prokaryotic cells.[2][3]

The wordtransfectionis aportmanteauof the prefixtrans-and the word "infection."Geneticmaterial (such assupercoiled plasmid DNAorsiRNAconstructs), may be transfected. Transfection ofanimal cellstypically involves opening transient pores or "holes" in thecell membraneto allow the uptake of material. Transfection can be carried out usingcalcium phosphate(i.e.tricalcium phosphate), byelectroporation,by cell squeezing, or by mixing acationiclipidwith the material to produceliposomesthat fuse with the cell membrane and deposit their cargo inside.

Transfection can result in unexpected morphologies and abnormalities in target cells.

Terminology

edit

The meaning of the term has evolved.[4]The original meaning of transfection was "infection by transformation", i.e., introduction of genetic material, DNA or RNA, from aprokaryote-infecting virus orbacteriophageinto cells, resulting in an infection. For work with bacterial and archaeal cells transfection retains its original meaning as a special case of transformation. Because the term transformation had another sense in animal cell biology (a genetic change allowing long-term propagation in culture, or acquisition of properties typical of cancer cells), the term transfection acquired, for animal cells, its present meaning of a change in cell properties caused by introduction of DNA.[citation needed]

Methods

edit

There are various methods of introducing foreignDNAinto a eukaryoticcell:some rely on physical treatment (electroporation, cell squeezing,nanoparticles,magnetofection); others rely on chemical materials or biological particles (viruses) that are used as carriers. There are many different methods of gene delivery developed for various types of cells and tissues, from bacterial to mammalian. Generally, the methods can be divided into three categories: physical, chemical, and biological.[5]

Physical methods includeelectroporation,microinjection,gene gun,impalefection,hydrostatic pressure,continuous infusion, and sonication. Chemicals include methods such aslipofection,which is a lipid-mediated DNA-transfection process utilizing liposome vectors. It can also include the use of polymeric gene carriers (polyplexes).[6]Biological transfection is typically mediated byviruses,utilizing the ability of a virus to inject its DNA inside a host cell. A gene that is intended for delivery is packaged into a replication-deficient viral particle. Viruses used to date includeretrovirus,lentivirus,adenovirus,adeno-associated virus,andherpes simplex virus.[citation needed]

Physical methods

edit
Electroporator with square wave and exponential decay waveforms for in vitro, in vivo, adherent cell and 96 well electroporation applications. Manufactured by BTX Harvard Apparatus, Holliston MA USA.

Physical methods are the conceptually simplest, using some physical means to force the transfected material into the target cell's nucleus. The most widely used physical method iselectroporation,where short electrical pulses disrupt the cell membrane, allowing the transfected nucleic acids to enter the cell.[5]Other physical methods use different means to poke holes in the cell membrane:Sonoporationuses high-intensity ultrasound (attributed mainly to thecavitationof gas bubbles interacting with nearby cell membranes),optical transfectionuses a highly focused laser to form a ~1 μm diameter hole.[7]

Several methods use tools that force the nucleic acid into the cell, namely:microinjectionof nucleic acid with a fine needle;[5]biolistic particle delivery,in which nucleic acid is attached to heavy metal particles (usually gold) and propelled into the cells at high speed;[8]andmagnetofection,where nucleic acids are attached to magneticiron oxideparticles and driven into the target cells by magnets.[8]

Hydrodynamic deliveryis a method used in mice and rats, in which nucleic acids can be delivered to the liver by injecting a relatively large volume in the blood in less than 10 seconds; nearly all of the DNA is expressed in the liver by this procedure.[9]

Chemical methods

edit

Chemical-based transfectioncan be divided into several kinds:cyclodextrin,[10]polymers,[11]liposomes, or nanoparticles[12](with or without chemical or viral functionalization. See below).

  • One of the cheapest methods usescalcium phosphate,originally discovered byF. L. GrahamandA. J. van der Ebin 1973[13](see also[14]).HEPES-buffered saline solution (HeBS) containing phosphate ions is combined with acalcium chloridesolution containing the DNA to be transfected. When the two are combined, a fine precipitate of the positively charged calcium and the negatively charged phosphate will form, binding the DNA to be transfected on its surface. The suspension of the precipitate is then added to the cells to be transfected (usually a cell culture grown in a monolayer). By a process not entirely understood, the cells take up some of the precipitate, and with it, the DNA. This process has been a preferred method of identifying many oncogenes.[15]
  • Another method is the use ofcationic polymerssuch asDEAE-dextranorpolyethylenimine(PEI). The negatively charged DNA binds to thepolycationand the complex is taken up by the cell viaendocytosis.
  • Lipofection(orliposometransfection) is a technique used to inject genetic material into a cell by means ofliposomes,which arevesiclesthat can easily merge with thecell membranesince they are both made of aphospholipid bilayer.[16]Lipofection generally uses a positively charged (cationic) lipid (cationic liposomesor mixtures) to form an aggregate with the negatively charged (anionic) genetic material.[17]This transfection technology performs the same tasks as other biochemical procedures utilizing polymers,DEAE-dextran,calcium phosphate,andelectroporation.The efficiency of lipofection can be improved by treating transfected cells with a mildheat shock.[18]
  • Fugeneis a series of widely used proprietary non-liposomal transfection reagents capable of directly transfecting a wide variety of cells with high efficiency and low toxicity.[19][20][21][22]
  • Dendrimeris a class of highly branched molecules based on various building blocks and synthesized through a convergent or a divergent method. Thesedendrimersbind the nucleic acids to form dendriplexes that then penetrate the cells.[23][24]

Viral methods

edit

DNA can also be introduced into cells usingvirusesas a carrier. In such cases, the technique is calledtransduction,and the cells are said to be transduced.Adenoviralvectors can be useful for viral transfection methods because they can transfer genes into a wide variety of human cells and have high transfer rates.[2]Lentiviral vectors are also helpful due to their ability to transduce cells not currently undergoing mitosis.

Protoplast fusion is a technique in which transformed bacterial cells are treated with lysozyme in order to remove the cell wall. Following this, fusogenic agents (e.g., Sendai virus, PEG, electroporation) are used in order to fuse the protoplast carrying the gene of interest with the target recipient cell. A major disadvantage of this method is that bacterial components are non-specifically introduced into the target cell as well.

Stable and transient transfection

edit

Stable and transient transfection differ in their long term effects on a cell; a stably transfected cell will continuously express transfected DNA and pass it on todaughter cells,while a transiently transfected cell will express transfected DNA for a short amount of time and not pass it on to daughter cells.

For some applications of transfection, it is sufficient if the transfected genetic material is only transiently expressed. Since the DNA introduced in the transfection process is usually not integrated into the nuclear genome, the foreign DNA will be diluted throughmitosisor degraded.[5]Cell lines expressing theEpstein–Barr virus(EBV) nuclear antigen 1 (EBNA1) or the SV40 large-T antigen allow episomal amplification of plasmids containing the viral EBV (293E) or SV40 (293T) origins of replication, greatly reducing the rate of dilution.[25]

If it is desired that the transfected gene actually remain in the genome of the cell and its daughter cells, a stable transfection must occur. To accomplish this, amarker geneis co-transfected, which gives the cell some selectable advantage, such as resistance towards a certaintoxin.Some (very few) of the transfected cells will, by chance, have integrated the foreign genetic material into their genome. If the toxin is then added to the cell culture, only those few cells with the marker gene integrated into their genomes will be able toproliferate,while other cells will die. After applying this selective stress (selection pressure) for some time, only the cells with a stable transfection remain and can be cultivated further.[26]

Common agents for selecting stable transfection are:

RNA transfection

edit

RNA can also be transfected into cells to transiently express its coded protein, or to studyRNA decaykinetics. RNA transfection is often used in primary cells that do not divide.

siRNAscan also be transfected to achieve RNA silencing (i.e. loss of RNA and protein from the targeted gene). This has become a major application in research to achieve "knock-down"of proteins of interests (e.g. Endothelin-1[27]) with potential applications in gene therapy. Limitation of the silencing approach are the toxicity of the transfection for cells and potential "off-target" effects on the expression of other genes/proteins.

RNA can be purified from cells afterlysisor synthesized from freenucleotideseither chemically, or enzymatically using anRNA polymerasetotranscribeaDNAtemplate. As with DNA, RNA can be delivered to cells by a variety of means includingmicroinjection,electroporation,andlipid-mediated transfection.If the RNA encodes aprotein,transfected cells maytranslatethe RNA into the encoded protein.[28]If the RNA is a regulatory RNA (such as amiRNA), the RNA may cause other changes in the cell (such asRNAi-mediated knockdown).

Encapsulating the RNA molecule inlipid nanoparticleswas a breakthrough for producing viableRNA vaccines,solving a number of key technical barriers in delivering the RNA molecule into the human cell.[29][30]

RNA molecules shorter than about 25nt (nucleotides) largely evade detection by theinnate immune system,which is triggered by longer RNA molecules. Most cells of the body express proteins of the innate immune system, and upon exposure to exogenous long RNA molecules, these proteins initiate signaling cascades that result ininflammation.This inflammation hypersensitizes the exposed cell and nearby cells to subsequent exposure. As a result, while a cell can be repeatedly transfected with short RNA with few non-specific effects, repeatedly transfecting cells with even a small amount of long RNA can cause cell death unless measures are taken to suppress or evade the innate immune system (see "Long-RNA transfection" below).

Short-RNA transfection is routinely used in biological research to knock down the expression of a protein of interest (usingsiRNA) or to express or block the activity of amiRNA(using short RNA that acts independently of the cell'sRNAimachinery, and therefore is not referred to as siRNA). While DNA-based vectors (viruses,plasmids) that encode a short RNA molecule can also be used, short-RNA transfection does not risk modification of the cell's DNA, a characteristic that has led to the development of short RNA as a new class ofmacromoleculardrugs.[31]

Long-RNA transfection is the process of deliberately introducing RNA molecules longer than about 25nt into living cells. A distinction is made between short- and long-RNA transfection because exogenous long RNA molecules elicit aninnate immune responsein cells that can cause a variety of nonspecific effects includingtranslationblock,cell-cyclearrest, andapoptosis.

Endogenous vs. exogenous long RNA

edit

The innate immune system has evolved to protect againstinfectionby detectingpathogen-associated molecular patterns(PAMPs), and triggering a complex set of responses collectively known asinflammation.Many cells express specificpattern recognition receptors(PRRs) for exogenous RNA includingtoll-like receptor3,7,8 (TLR3,TLR7,TLR8),[32][33][34][35]the RNAhelicaseRIG1 (RARRES3),[36]protein kinase R(PKR, a.k.a. EIF2AK2),[37][38]members of the oligoadenylate synthetase family of proteins (OAS1,OAS2,OAS3), and others. All of these proteins can specifically bind to exogenous RNA molecules and trigger an immune response. The specific chemical, structural or other characteristics of long RNA molecules that are required for recognition by PRRs remain largely unknown despite intense study. At any given time, a typicalmammaliancell may contain several hundred thousand mRNA and other,regulatory long RNAmolecules. How cells distinguish exogenous long RNA from the large amount of endogenous long RNA is an important open question incell biology.Several reports suggest thatphosphorylationof the 5'-end of a long RNA molecule can influence itsimmunogenicity,and specifically that 5'-triphosphate RNA, which can be produced during viral infection, is more immunogenic than 5'-diphosphate RNA, 5'-monophosphate RNA or RNA containing no 5' phosphate.[39][40][41][42][43][44]However, in vitro-transcribed (ivT) long RNA containing a7-methylguanosine cap(present ineukaryoticmRNA) is also highly immunogenic despite having no 5' phosphate,[45]suggesting that characteristics other than 5'-phosphorylation can influence the immunogenicity of an RNA molecule.

Eukaryotic mRNA contains chemically modified nucleotides such asN6-methyladenosine,5-methylcytidine,and2'-O-methylatednucleotides. Although only a very small number of these modified nucleotides are present in a typical mRNA molecule, they may help prevent mRNA from activating the innate immune system by disruptingsecondary structurethat would resemble double-stranded RNA (dsRNA),[46][34]a type of RNA thought to be present in cells only during viral infection. The immunogenicity of long RNA has been used to study both innate andadaptive immunity.

Repeated long-RNA transfection

edit

Inhibiting only three proteins,interferon-β,STAT2,andEIF2AK2is sufficient to rescue humanfibroblastsfrom the cell death caused by frequent transfection with long, protein-encoding RNA.[45]Inhibiting interferon signaling disrupts the positive-feedback loop that normally hypersensitizes cells exposed to exogenous long RNA. Researchers have recently used this technique to expressreprogramming proteinsin primary humanfibroblasts.[47]

See also

edit

References

edit
  1. ^Transfectionat the U.S. National Library of MedicineMedical Subject Headings(MeSH)
  2. ^abc"Transfection".Protocols and Applications Guide.Promega. Archived fromthe originalon 25 June 2014.Retrieved25 October2014.
  3. ^Transduction, Geneticat the U.S. National Library of MedicineMedical Subject Headings(MeSH)
  4. ^"Transfection"atDorland's Medical Dictionary
  5. ^abcdKim TK, Eberwine JH (August 2010)."Mammalian cell transfection: the present and the future".Analytical and Bioanalytical Chemistry.397(8):3173–8.doi:10.1007/s00216-010-3821-6.PMC2911531.PMID20549496.
  6. ^Saul JM, Linnes MP, Ratner BD, Giachelli CM, Pun SH (November 2007). "Delivery of non-viral gene carriers from sphere-templated fibrin scaffolds for sustained transgene expression".Biomaterials.28(31):4705–16.doi:10.1016/j.biomaterials.2007.07.026.PMID17675152.
  7. ^Tsukakoshi M, Kurata S, Nomiya Y, et al. (1984). "A Novel Method of DNA Transfection by Laser Microbeam Cell Surgery".Applied Physics B: Photophysics and Laser Chemistry.35(3):135–140.Bibcode:1984ApPhB..35..135T.doi:10.1007/BF00697702.S2CID123250337.
  8. ^abMehier-Humbert S, Guy RH (April 2005). "Physical methods for gene transfer: improving the kinetics of gene delivery into cells".Adv Drug Deliv Rev.57(5):733–53.doi:10.1016/j.addr.2004.12.007.PMID15757758.
  9. ^Suda T, Liu D (2015). "Hydrodynamic Delivery".Nonviral Vectors for Gene Therapy - Physical Methods and Medical Translation.Advances in Genetics. Vol. 89. pp.89–111.doi:10.1016/bs.adgen.2014.10.002.ISBN9780128022726.PMID25620009.
  10. ^Menuel S, Fontanay S, Clarot I, Duval RE, Diez L, Marsura A (December 2008). "Synthesis and complexation ability of a novel bis- (guanidinium)-tetrakis-(beta-cyclodextrin) dendrimeric tetrapod as a potential gene delivery (DNA and siRNA) system. Study of cellular siRNA transfection".Bioconjugate Chemistry.19(12):2357–62.doi:10.1021/bc800193p.PMID19053312.
  11. ^Fischer D, von Harpe A, Kunath K, Petersen H, Li Y, Kissel T (2002). "Copolymers of ethylene imine and N-(2-hydroxyethyl)-ethylene imine as tools to study effects of polymer structure on physicochemical and biological properties of DNA complexes".Bioconjugate Chemistry.13(5):1124–33.doi:10.1021/bc025550w.PMID12236795.
  12. ^"Nanoparticle Based Transfection Reagents".Biology Transfection Research Resource.Transfection.ws. Archived fromthe originalon 21 April 2013.Retrieved30 September2009.
  13. ^Graham FL, van der Eb AJ (April 1973). "A new technique for the assay of infectivity of human adenovirus 5 DNA".Virology.52(2):456–67.doi:10.1016/0042-6822(73)90341-3.PMID4705382.
  14. ^Bacchetti S, Graham FL (April 1977)."Transfer of the gene for thymidine kinase to thymidine kinase-deficient human cells by purified herpes simplex viral DNA".Proceedings of the National Academy of Sciences of the United States of America.74(4):1590–4.Bibcode:1977PNAS...74.1590B.doi:10.1073/pnas.74.4.1590.PMC430836.PMID193108.
  15. ^Kriegler M (1991).Transfer and Expression: A Laboratory Manual.W. H. Freeman. pp.96–97.ISBN978-0-7167-7004-6.
  16. ^Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M (November 1987)."Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure".Proceedings of the National Academy of Sciences of the United States of America.84(21):7413–7.Bibcode:1987PNAS...84.7413F.doi:10.1073/pnas.84.21.7413.PMC299306.PMID2823261.
  17. ^Felgner JH, Kumar R, Sridhar CN, Wheeler CJ, Tsai YJ, Border R, Ramsey P, Martin M, Felgner PL (January 1994)."Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations".The Journal of Biological Chemistry.269(4):2550–61.doi:10.1016/S0021-9258(17)41980-6.PMID8300583.
  18. ^Pipes BL, Vasanwala FH, Tsang TC, Zhang T, Luo P, Harris DT (January 2005)."Brief heat shock increases stable integration of lipid-mediated DNA transfections".BioTechniques.38(1):48–52.doi:10.2144/05381bm05.PMID15679084.[permanent dead link‍]
  19. ^Jacobsen LB, Calvin SA, Colvin KE, Wright M (June 2004). "FuGENE 6 Transfection Reagent: the gentle power".Methods.Transfection of Mammalian Cells.33(2):104–12.doi:10.1016/j.ymeth.2003.11.002.PMID15121164.
  20. ^Hellgren I, Drvota V, Pieper R, Enoksson S, Blomberg P, Islam KB, Sylvén C (August 2000)."Highly efficient cell-mediated gene transfer using non-viral vectors and FuGene6: in vitro and in vivo studies".Cellular and Molecular Life Sciences.57(8–9):1326–33.doi:10.1007/PL00000769.PMC11146917.PMID11028922.S2CID27916034.
  21. ^Lakshmipathy U, Thyagarajan B (2011).Primary and Stem Cells: Gene Transfer Technologies and Applications(1st ed.). Wiley-Blackwell.ISBN978-0-470-61074-9.
  22. ^Arnold AS, Laporte V, Dumont S, Appert-Collin A, Erbacher P, Coupin G, Levy R, Poindron P, Gies JP (February 2006). "Comparing reagents for efficient transfection of human primary myoblasts: FuGENE 6, Effectene and ExGen 500".Fundamental & Clinical Pharmacology.20(1):81–9.doi:10.1111/j.1472-8206.2005.00344.x.PMID16448398.S2CID42585711.
  23. ^Sapra, Rachit; Verma, Ram P.; Maurya, Govind P.; Dhawan, Sameer; Babu, Jisha; Haridas, V. (13 November 2019). "Designer Peptide and Protein Dendrimers: A Cross-Sectional Analysis".Chemical Reviews.119(21):11391–11441.doi:10.1021/acs.chemrev.9b00153.ISSN0009-2665.PMID31556597.S2CID203435702.
  24. ^Heitz, Marc; Javor, Sacha; Darbre, Tamis; Reymond, Jean-Louis (21 August 2019). "Stereoselective pH Responsive Peptide Dendrimers for siRNA Transfection".Bioconjugate Chemistry.30(8):2165–2182.doi:10.1021/acs.bioconjchem.9b00403.ISSN1043-1802.PMID31398014.S2CID199519310.
  25. ^Durocher Y, Perret S, Kamen A (January 2002)."High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells".Nucleic Acids Research.30(2): 9e–9.doi:10.1093/nar/30.2.e9.PMC99848.PMID11788735.
  26. ^Fanelli A (2016)."The Science of Stable Cell Line Generation".Retrieved23 December2017.
  27. ^Mawji IA, Marsden PA (June 2006)."RNA transfection is a versatile tool to investigate endothelin-1 posttranscriptional regulation".Experimental Biology and Medicine.231(6):704–708.doi:10.3181/00379727-231-2310704(inactive 1 November 2024).PMID16740984.{{cite journal}}:CS1 maint: DOI inactive as of November 2024 (link)
  28. ^Herb M, Farid A, Gluschko A, Krönke M, Schramm M (November 2019)."Highly Efficient Transfection of Primary Macrophages with In Vitro Transcribed mRNA".Journal of Visualized Experiments(153).doi:10.3791/60143.PMID31762462.
  29. ^Cooney, Elizabeth (1 December 2020)."How nanotechnology helps mRNA Covid-19 vaccines work".Stat.Retrieved3 December2020.
  30. ^Foley, Katherine Ellen (22 December 2020)."The first Covid-19 vaccines have changed biotech forever".Quartz.Quartz Media.Retrieved11 January2021.
  31. ^Tansey B (11 August 2006)."Macular degeneration treatment interferes with RNA messages".San Francisco Chronicle.
  32. ^Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001). "Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3".Nature.413(6857):732–738.Bibcode:2001Natur.413..732A.doi:10.1038/35099560.PMID11607032.S2CID4346537.
  33. ^Kariko K, Ni H, Capodici J, Lamphier M, Weissman D (2004)."mRNA is an endogenous ligand for Toll-like receptor 3".J Biol Chem.279(13):12542–12550.doi:10.1074/jbc.M310175200.PMID14729660.
  34. ^abKariko K, Buckstein M, Ni H, Weissman D (2005)."Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA".Immunity.23(2):165–175.doi:10.1016/j.immuni.2005.06.008.PMID16111635.
  35. ^Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C (2004)."Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA".Science.303(5663):1529–1531.Bibcode:2004Sci...303.1529D.doi:10.1126/science.1093616.PMID14976261.S2CID33144196.
  36. ^Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, et al. (2004). "The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses".Nat Immunol.5(7):730–737.doi:10.1038/ni1087.PMID15208624.S2CID34876422.
  37. ^Das HK, Das A, Ghosh-Dastidar P, Ralston RO, Yaghmai B, et al. (1981)."Protein synthesis in rabbit reticulocytes. Purification and characterization of a double-stranded RNA-dependent protein synthesis inhibitor from reticulocyte lysates".J Biol Chem.256(12):6491–6495.doi:10.1016/S0021-9258(19)69192-1.PMID7240221.
  38. ^Levin DH, Petryshyn R, London IM (1981)."Characterization of purified double-stranded RNA-activated eIF-2 alpha kinase from rabbit reticulocytes".J Biol Chem.256(14):7638–7641.doi:10.1016/S0021-9258(19)69008-3.PMID6265457.
  39. ^Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, et al. (2006)."5'-triphosphate RNA is the ligand for RIG-I".Science.314(5801):994–997.Bibcode:2006Sci...314..964H.doi:10.1126/science.1132505.PMID17038590.S2CID22436759.
  40. ^Saito T; Owen DM; Jiang F; Marcotrigiano J; Gale M, Jr. (2008)."Innate immunity induced by composition-dependent RIG-I recognition of Hepatitis C virus RNA".Nature.454(7203):523–527.Bibcode:2008Natur.454..523S.doi:10.1038/nature07106.PMC2856441.PMID18548002.
  41. ^Takahasi K, Yoneyama M, Nishihori T, Hirai R, Kumeta H, et al. (2008)."Nonself RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune responses".Mol Cell.29(4):428–440.doi:10.1016/j.molcel.2007.11.028.PMID18242112.
  42. ^Yoneyama M, Fujita T (2008)."Structural mechanism of RNA recognition by the RIG-I-like receptors".Immunity.29(2):178–181.doi:10.1016/j.immuni.2008.07.009.PMID18701081.
  43. ^Schmidt A, Schwerd T, Hamm W, Hellmuth JC, Cui S, et al. (2009)."5'-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I".Proc Natl Acad Sci USA.106(29):12067–12072.Bibcode:2009PNAS..10612067S.doi:10.1073/pnas.0900971106.PMC2705279.PMID19574455.
  44. ^Schlee M, Roth A, Hornung V, Hagmann CA, Wimmenauer V, et al. (2009)."Recognition of 5'-triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative strand virus".Immunity.31(1):25–34.doi:10.1016/j.immuni.2009.05.008.PMC2824854.PMID19576794.
  45. ^abAngel M, Yanik MF (2010)."Innate Immune Suppression Enables Frequent Transfection with RNA Encoding Reprogramming Proteins".PLOS ONE.5(7): e11756.Bibcode:2010PLoSO...511756A.doi:10.1371/journal.pone.0011756.PMC2909252.PMID20668695.
  46. ^Herb M, Farid A, Gluschko A, Krönke M, Schramm M (November 2019)."Highly Efficient Transfection of Primary Macrophages with In Vitro Transcribed mRNA".Journal of Visualized Experiments(153).doi:10.3791/60143.PMID31762462.
  47. ^Trafton A (26 July 2010)."RNA offers a safer way to reprogram cells".MIT News Office.

Further reading

edit
edit
Scholiahas a profile fortransfection(Q1429031).
Retrieved from "https://en.wikipedia.org/w/index.php?title=Transfection&oldid=1275232317"